Cellectis: Press Review

Since the announcement of Cellectis' investment in North Carolina, many media explained the whole story and described the FACCC role.

  • News and Observer: "French biopharm company picks Raleigh for its first US manufacturing facility, creating 200 jobs", by Zachery EANES 
    "The addition of Cellectis, whose main office is in Paris, adds to the growing number of French biotech companies that are operating in North Carolina. Currently, more than 300 French companies, across all sectors, operate in the state, said Marie-Claire Ribeill, executive director of the French-American Chamber of Commerce, which helped connect state officials and the company."
    "One French company with a large presence in the area already is bioMérieux, which makes about half the world’s vials used by hospitals and labs to detect patients’ blood samples for bacterial infections. That company now employs around 1,000 people in Durham County, and several other French companies also operate in the Triangle."https://www.newsobserver.com/news/business/article227212059.html

  • NC Biotech Center: "NC’s Gene Therapy Status Boosted by Cellectis Plan for $68.6M Cancer Immunotherapy Facility" by Jim Shamp
    “There is a 300-year tradition of friendship between France and America, and the arrival of Cellectis is one more step in the development and reinforcement of this solid relationship,” said Marie-Claire Ribeill, executive director of the Raleigh-based French American Chamber of Commerce of the Carolinas (FACCC).
    “It is also a testimony of the hard work put in by all the teams of economic actors in North Carolina and the FACCC to highlight the incredible advantages to working and living in this state,” added Ribeill, who is also an honorary consul of France. 
    “FACCC is working actively to bring N.C. to the attention of the French business community, and was thrilled to work with NCBiotech toward locating and connecting with this new addition to our biotech landscape. We are looking forward to helping bring more French companies to this area. We are also a relay of the economic trends in France, where the new slogan is, ‘France is back,’ and we hope to work hand-in-hand with N.C. to capitalize on all of these new opportunities.”

  • Triangle Business Journal: "How the Triangle's lifesciences ecosystem helped Cellectis pick Raleigh for expansion" by Lauren Ohnesorge
    "[Marie-Claire] Ribeill said she became aware of the Cellectis opportunity more than a year ago – but that it was favoring “another location,” purportedly New Jersey, which Commerce confirms had offered a competing incentives package worth $8 million. But there were problems with the site, Ribeill says.
    Cellectis had bold ambitions, with plans to get a site up and running by 2021 in time for planned commercialization approval in 2022. And New Jersey couldn’t deliver. It was “less far along” when it comes to life sciences training opportunities through its local colleges, Bill Monteith, senior vice president U.S. Manufacturing for Cellectis, says.  Couple that with he describes as North Carolina’s “diversity of resources,” and North Carolina started to inch up on the short list.
    Economic developers in North Carolina, recognizing the opportunity, worked swiftly last fall, tagging in Bill Bullock, vice president of economic development and statewide operations for the North Carolina Biotechnology Center. It was Bullock who flew to Paris directly last November to meet face to face with the company."


Share this page Share on FacebookShare on TwitterShare on Linkedin